NasdaqGM:ARDXBiotechs
Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling
U.S. federal appellate court rules that Ardelyx’s Xphozah will be included in Medicare’s ESRD bundled payment system, ending separate reimbursement.
The decision resolves a long-running legal dispute over how the drug is treated under Medicare’s payment structure for dialysis care.
The ruling affects how dialysis providers are paid for Xphozah and may influence pricing decisions and product positioning for NasdaqGM:ARDX.
Ardelyx, the biopharmaceutical company behind Xphozah, focuses on...